The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Affiliation
University of Leuven
Country
Belgium
1. Current Status, Position
Prof Dr Paul Declerck (PharmD, PhD) currently is Professor in Pharmaceutical Biotechnology and Dean at the Faculty of Pharmaceutical Sciences at the University of Leuven, Belgium.
In 1991 he was appointed professor of Pharmaceutical Biotechnology at the Faculty of Pharmaceutical Sciences. He became full professor in 1997. He is Research Director of the Laboratory for Therapeutic and Diagnostic Antibodies at the Department of Pharmaceutical and Pharmacological Sciences (KU Leuven).
2. Education
Prof Dr Paul Declerck, PharmD, PhD, obtained his Ph.D. in Pharmaceutical Sciences from the KU Leuven (Belgium) in 1984. After a post-doctoral training in the Laboratory of Biochemical Cytology (Prof. Dr. C. de Duve) at the Rockefeller University in New York, he joined in 1986 the Center for Molecular and Vascular Biology (Prof. D. Collen) at the KU Leuven.
3. Research Area
Prof Dr Declerck’s research is focused on structure-function relationships of (recombinant) proteins and on the development of monoclonal antibodies for research, diagnostic and therapeutic purposes. He has expertise in the area of recombinant proteins, monoclonal antibody technology, biotechnology, drug development, structure-function relationship in proteins, biosimilars.
4. Conflict of interest: Prof Dr Paul Declerck receives speakers’ fee and/or honoraria for lectures or (non-product specific) advisory board meetings